Aytu Biopharma Inc
F:AY20
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Aytu Biopharma Inc
F:AY20
|
US |
|
Medipal Holdings Corp
OTC:MEPDF
|
JP |
|
Delta Lithium Ltd
ASX:DLI
|
AU |
|
S
|
SSE PLC
DUS:SCT
|
UK |
|
A
|
Andritz AG
DUS:AZ2
|
AT |
|
Cullinan Oncology Inc
NASDAQ:CGEM
|
US |
|
Thule Group AB
OTC:THLPF
|
SE |
|
Takashimaya Co Ltd
TSE:8233
|
JP |
|
AKR Corporindo Tbk PT
IDX:AKRA
|
ID |
|
Dali Foods Group Co Ltd
F:05M
|
CN |
|
Stevva Corp
OTC:STVA
|
GR |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
US |
|
C
|
Compagnie Generale des Etablissements Michelin SCA
XHAM:MCH
|
FR |
|
S
|
Sensient Technologies Corp
F:SSF
|
US |
|
C
|
Corcept Therapeutics Inc
XMUN:HTD
|
US |
|
T
|
Teixeira Duarte SA
XMUN:TXC2
|
PT |
|
M
|
Mogo Inc
F:SGCC
|
CA |
|
Sartorius AG
F:SRT0
|
DE |
|
C
|
CK Asset Holdings Ltd
SWB:1CK
|
HK |
|
B
|
Bendigo and Adelaide Bank Ltd
F:BDJ
|
AU |
|
S
|
Sunindo Pratama PT Tbk
IDX:SUNI
|
ID |
|
Botanix Pharmaceuticals Ltd
ASX:BOT
|
AU |
|
A
|
Ascot Resources Ltd
OTC:AOTVD
|
CA |
|
Pegasystems Inc
NASDAQ:PEGA
|
US |
Wall St Price Targets
AY20 Price Targets Summary
Aytu Biopharma Inc
According to Wall Street analysts, the average 1-year price target for AY20 is 14.575 EUR with a low forecast of 10.634 EUR and a high forecast of 22.9 EUR.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is AY20's stock price target?
Price Target
14.575
EUR
According to Wall Street analysts, the average 1-year price target for AY20 is 14.575 EUR with a low forecast of 10.634 EUR and a high forecast of 22.9 EUR.
What is the Revenue forecast for Aytu Biopharma Inc?
Projected CAGR
13%
Over the last 9 years, the compound annual growth rate for Revenue has been 43%. The projected CAGR for the next 3 years is 13%.
What is the Gross Profit forecast for Aytu Biopharma Inc?
Projected CAGR
13%
Over the last 9 years, the compound annual growth rate for Gross Profit has been 45%. The projected CAGR for the next 3 years is 13%.
What is the Operating Income forecast for Aytu Biopharma Inc?
Projected CAGR
78%
The compound annual growth rate for Operating Income over the next 3 years is 78%.
